{"id":"srp-4045","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Muscle pain"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL597461","moleculeType":"Small molecule","molecularWeight":"316.26"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"SRP-4045 uses a viral vector to deliver a micro-dystrophin gene to muscle cells, allowing them to produce a truncated but functional form of the dystrophin protein. This can help to alleviate the symptoms of Duchenne muscular dystrophy by reducing muscle damage and improving muscle function.","oneSentence":"SRP-4045 is a micro-dystrophin gene therapy that aims to treat Duchenne muscular dystrophy by providing a functional copy of the dystrophin gene.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:01.846Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Duchenne muscular dystrophy"}]},"trialDetails":[{"nctId":"NCT02500381","phase":"PHASE3","title":"Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)","status":"COMPLETED","sponsor":"Sarepta Therapeutics, Inc.","startDate":"2016-09-28","conditions":"Duchenne Muscular Dystrophy","enrollment":228},{"nctId":"NCT06606340","phase":"","title":"A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice","status":"ENROLLING_BY_INVITATION","sponsor":"Sarepta Therapeutics, Inc.","startDate":"2019-01-07","conditions":"Duchenne Muscular Dystrophy","enrollment":300},{"nctId":"NCT03532542","phase":"PHASE3","title":"An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy","status":"TERMINATED","sponsor":"Sarepta Therapeutics, Inc.","startDate":"2018-08-02","conditions":"Duchenne Muscular Dystrophy","enrollment":171},{"nctId":"NCT04179409","phase":"PHASE2","title":"A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications.","status":"COMPLETED","sponsor":"Kevin Flanigan","startDate":"2020-02-18","conditions":"Duchenne Muscular Dystrophy","enrollment":3},{"nctId":"NCT02530905","phase":"PHASE1","title":"Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients","status":"COMPLETED","sponsor":"Sarepta Therapeutics, Inc.","startDate":"2015-10-08","conditions":"Duchenne Muscular Dystrophy","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Casimersen","AMONDYS 45"],"phase":"phase_3","status":"active","brandName":"SRP-4045","genericName":"SRP-4045","companyName":"Sarepta Therapeutics, Inc.","companyId":"sarepta-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SRP-4045 is a micro-dystrophin gene therapy that aims to treat Duchenne muscular dystrophy by providing a functional copy of the dystrophin gene. Used for Duchenne muscular dystrophy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":3,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}